kinetin and Rosacea studies

Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects.
cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.
kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group.

Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).

Research Excerpts

Excerpt	Relevance	Reference
"Many patients with rosacea are unable to tolerate extended treatment periods with topical agents because of the unusually high skin sensitivity that often accompanies rosacea."	6.73	Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. ( Kormeili, T; Kricorian, GJ; McCullough, JL; Weinstein, GD; Wu, JJ, 2007)
"Many patients with rosacea are unable to tolerate extended treatment periods with topical agents because of the unusually high skin sensitivity that often accompanies rosacea."	2.73	Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. ( Kormeili, T; Kricorian, GJ; McCullough, JL; Weinstein, GD; Wu, JJ, 2007)
"Acne and rosacea are common inflammatory processes historically classified in the same disease category, but evolving understanding of their disparate pathophysiology and exacerbating factors have generated an enormous armamentarium of therapeutic possibilities."	2.53	Over-the-counter treatments for acne and rosacea. ( Rosamilia, LL, 2016)

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Erythema Severity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Rosamilia, LL	1
Wu, JJ	1
Weinstein, GD	1
Kricorian, GJ	1
Kormeili, T	1
McCullough, JL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effects of PRK 124 (0.125%) Lotion in Acne Rosacea[NCT00580723]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2007-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Measured by percent improvement on a scale of 0-4. Subjects received a 0 for no improvement, 1 for less than twenty-five percent improvement, a 2 for twenty-five to fifty percent improvement, a 3 for fifty to seventy-five percent improvement and a 4 for greater than seventy-five percent improvement. Mean scores from all continuing 16 participants were averaged for each encounter, for a total of 8 visits. The percent improvement in mean erythema severity was calculated by comparing the change in mean scores at week 48 to mean scores assessed at baseline. (NCT00580723)
Timeframe: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48

Inflammatory Lesion Count

Intervention	Erythema percent improvement (Mean)
Topical PRK 124	44.53

Lesion counts were numerically summed for each patient at each encounter, and the average lesion count was calculated from all continuing 16 subjects at each visit, for a total of 8 visits. Percent improvement (reduction in lesion number) was assessed by comparing the average number of lesions at week 48 to the average number of lesions assessed at baseline. (NCT00580723)
Timeframe: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48

Telangiectasia Severity

Intervention	Percent change in number of lesions (Mean)
Topical PRK 124	89

Measured by percent improvement on a scale of 0-4. Subjects received a 0 for no improvement, 1 for less than twenty-five percent improvement, a 2 for twenty-five to fifty percent improvement, a 3 for fifty to seventy-five percent improvement and a 4 for greater than seventy-five percent improvement. Mean scores from all continuing 16 participants were averaged for each encounter, for a total of 8 visits. The percent improvement in mean telangiectasia severity was calculated by comparing the change in mean scores at week 48 to mean scores assessed at baseline. (NCT00580723)
Timeframe: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48

kinetin and Rosacea